ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Investigation of the protective effects of hesperidin against nivolumab toxicity in rat testis tissue.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hesperidin attenuates gentamicin-induced testicular toxicity via modulation of the PI3K/AKT signaling pathway.BMC complementary medicine and therapies · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nivolumab is an effective immunotherapy drug, but its long-term side effects remain unknown. This study was designed as a preventive experimental model to investigate the potential preventive and protective effects of hesperidin against testicular toxicity that may be caused by nivolumab. Thirty-two male Wistar Albino rats were used in the study (n = 8 per group). The groups were as follows: control, nivolumab (3 mg/kg), hesperidin (50 mg/kg), and nivolumab (3 mg/kg) + hesperidin (50 mg/kg). After the completion of drug administration, blood and testicular tissues were collected under anesthesia. ELISA, real-time PCR, and histopathological analyses were performed to assess the biochemical, molecular, and histopathological changes in the testicular tissue. Histopathological analysis revealed that nivolumab caused notable damage to the testicular tissue. Severe cytoplasmic expression of 8-hydroxyguanosine (8-OHdG) and Caspase-3 was observed in spermatocytes, indicating oxidative stress and apoptosis. Hesperidin administration attenuated these histopathological changes. Biochemical analysis showed that nivolumab disrupted the balance of total oxidants and antioxidants, leading to oxidative stress, whereas hesperidin enhanced antioxidant activity and reduced oxidative damage. Additionally, nivolumab significantly reduced serum testosterone levels, while hesperidin increased testosterone levels. In terms of molecular pathways, nivolumab downregulated PI3K, AKT, and MTOR expressions, disrupting this signaling cascade, while hesperidin restored these expressions to levels closer to the control group. Nivolumab also reduced PD-1 expression, but hesperidin did not alter PD-1 expression levels. This preventive experimental design demonstrated that nivolumab caused oxidative damage and histopathological changes in rat testicular tissue, whereas hesperidin provided preventive protection against these adverse effects through its antioxidant and anti-apoptotic properties.
Indexed as
Identifiers
41283999What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.